Table 1 Characteristics of the baseline CoMMpass cohort
Characteristic | n = 1,143 |
|---|---|
Age at diagnosis, year | |
Median (range) | 63 (27–93) |
Distribution, no. (%) | |
<55 year | 239 (20.9) |
55–64 year | 400 (35.0) |
65–74 year | 358 (31.3) |
≥75 year | 146 (12.8) |
Sex, no. (%) | |
Male | 690 (60.4) |
Female | 453 (39.6) |
Race, no. (%) | |
White | 742 (64.9) |
Black | 161 (14.1) |
Asian | 18 (1.6) |
Other/unknown | 222 (19.4) |
ISS, no. (%) | |
I | 401 (35.1) |
II | 401 (35.1) |
III | 311 (27.2) |
Unknown | 30 (2.6) |
Type of myeloma, no. (%) | n = 971 |
Heavy chain | |
IgG | 568 (58.5) |
IgA | 169 (17.4) |
IgM | 2 (0.2) |
Biclonal | 11 (1.1) |
Negative | 123 (12.7) |
Unknown | 98 (10.1) |
Light chain | |
IgK | 547 (56.3) |
IgL | 322 (33.2) |
Biclonal | 15 (1.5) |
Negative | 25 (2.6) |
Unknown | 62 (6.4) |
Ploidy statusa, no. (%) | n = 871 |
HRD | 498 (57.2) |
NHRD | 373 (42.8) |
Immunoglobulin translocationsa, no (%); IgH, IgK and IgL | n = 851 |
CCND1 | 170 (20.0), 168, 2, 0 |
CCND2 | 10 (1.2), 5, 1, 4 |
CCND3 | 15 (1.8), 13, 0, 2 |
MAF | 34 (4.0), 33, 1, 0 |
MAFA | 6 (0.7), 5, 1, 0 |
MAFB | 11 (1.3), 9, 1, 1 |
MYC | 122 (14.3), 55, 18, 49 |
NSD2/WHSC1/MMSET | 109 (12.8), 108, 1, 0 |
MYC structural events, no. (%) | n = 851 |
MYC STRb | 251 (29.5%) |
Common copy number alterationsa, no. (%) | n = 871 |
del(1p22) | 212 (24.3) |
gain(1q21) | 307 (35.2) |
del(13q14) | 453 (52.0) |
del(17p13) | 109 (12.5) |
ECOG performancec, no. (%) | n = 844 |
0 | 295 (35.0) |
1 | 406 (48.1) |
2 | 99 (11.7) |
3 | 38 (4.5) |
4 | 6 (0.7) |
Cytogenetic risk profiled | n = 832 |
Standard risk | 585 (70.3) |
High risk | 247 (29.7) |
